{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:43:19Z","timestamp":1767836599583,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T00:00:00Z","timestamp":1438732800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Royal Dutch Pharmacists Association, KNMP","award":["2014"],"award-info":[{"award-number":["2014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s11096-015-0174-4","type":"journal-article","created":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T11:09:35Z","timestamp":1438686575000},"page":"1128-1135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands"],"prefix":"10.1007","volume":"37","author":[{"given":"Susan","family":"Hanemaaijer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fong","family":"Sodihardjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemieke","family":"Horikx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Wensing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A. G. M.","family":"De Smet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel L.","family":"Bouvy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Teichert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,5]]},"reference":[{"key":"174_CR1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.beha.2013.07.009","volume":"26","author":"R Shameem","year":"2013","unstructured":"Shameem R, Ansell J. Disadvantages of VKA and requirements for novel anticoagulants. Best Pract Res Clin Haematol. 2013;26:103\u201314.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"19","key":"174_CR2","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1093\/hmg\/ddp309","volume":"18","author":"M Teichert","year":"2009","unstructured":"Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden A, van Schaik R, Hofman A, et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet. 2009;18(19):3758\u201368.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"174_CR3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/clpt.2008.294","volume":"85","author":"M Teichert","year":"2009","unstructured":"Teichert M, van Schaik R, Hofman A, Uitterlinden A, de Smet P, Stricker B, et al. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin Pharmacol Ther. 2009;85(4):379\u201386.","journal-title":"Clin Pharmacol Ther"},{"key":"174_CR4","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1161\/STROKEAHA.111.000387","volume":"44","author":"K Bauer","year":"2013","unstructured":"Bauer K. Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal. Stroke. 2013;44:S38\u201340.","journal-title":"Stroke"},{"issue":"3","key":"174_CR5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.18553\/jmcp.2009.15.3.244","volume":"15","author":"W Baker","year":"2009","unstructured":"Baker W, Cios D, Sander S, Coleman C. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15(3):244\u201352.","journal-title":"J Manag Care Pharm"},{"issue":"11","key":"174_CR6","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jacc.2014.07.010","volume":"64","author":"A Blann","year":"2014","unstructured":"Blann A, Lip G. Laboratory monitoring of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64(11):1140\u20132.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"174_CR7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/europace\/euu311","volume":"17","author":"B Vrijens","year":"2015","unstructured":"Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015;17(4):514\u201323.","journal-title":"Europace"},{"key":"174_CR8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pop.2012.11.011","volume":"40","author":"C Dittus","year":"2013","unstructured":"Dittus C, Ansell J. The evolution of oral anticoagulant therapy. Prim Care. 2013;40:109\u201334.","journal-title":"Prim Care"},{"key":"174_CR9","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","volume":"31","author":"A Camm","year":"2010","unstructured":"Camm A, Kirchhof P, Lip G, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation. Eur Heart J. 2010;31:2369\u2013429.","journal-title":"Eur Heart J"},{"key":"174_CR10","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jacc.2012.02.008","volume":"59","author":"R Caterina De","year":"2012","unstructured":"De Caterina R, Husted S, Wallentin L, et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes. J Am Coll Cardiol. 2012;59:1413\u201325.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"174_CR11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2009-09-241851","volume":"115","author":"D Garcia","year":"2010","unstructured":"Garcia D, Libby E, Crowther M. The new oral anticoagulants. Blood. 2010;115(1):15\u201320.","journal-title":"Blood"},{"key":"174_CR12","unstructured":"Schalij M, Dubois E, Boersma L, Huisman M, Middeldorp S, Dijk van E, et al. Leidraad begeleide introductie nieuwe orale antistollingsmiddelen. 2012. http:\/\/www.knmpnl\/downloads\/samenwerken-kennis-delen\/ketenzorg\/LeidraadNOACpdf . Accessed 6 Feb 2014."},{"key":"174_CR13","unstructured":"College voor Zorgverzekeringen. FarmacotherapeutischKompas. 2015. www.fkcvznl . Accessed 9 Apr 2015."},{"issue":"12","key":"174_CR14","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"S Connolly","year":"2010","unstructured":"Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2010;361(12):1139\u201351.","journal-title":"N Engl J Med"},{"key":"174_CR15","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"M Patel","year":"2011","unstructured":"Patel M, Mahaffey K, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u20139.","journal-title":"N Engl J Med"},{"issue":"11","key":"174_CR16","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"C Granger","year":"2011","unstructured":"Granger C, Alexander J, McMurray J, Lopes R, Hylek E, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med"},{"issue":"24","key":"174_CR17","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"361","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar A, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342\u201352.","journal-title":"N Engl J Med"},{"issue":"36","key":"174_CR18","first-page":"2499","volume":"364","author":"G Landman","year":"2011","unstructured":"Landman G, Gans R. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2011;364(36):2499\u2013510.","journal-title":"N Engl J Med"},{"key":"174_CR19","author":"A G\u00f3mez-Outes","year":"2013","unstructured":"G\u00f3mez-Outes A, Terleira-Fern\u00e1ndez A, Calvo-Rojas G, Su\u00e1rez-Gea M, Vargas-Castrill\u00f3n E. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis. 2013;. doi: 10.1155\/2013\/640723 .","journal-title":"Thrombosis"},{"issue":"21","key":"174_CR20","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1161\/CIRCULATIONAHA.113.002332","volume":"128","author":"A Majeed","year":"2013","unstructured":"Majeed A, Hwang H, Connolly S, Eikelboom J, Ezekowitz M, Wallentin L, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013;128(21):2325\u201332.","journal-title":"Circulation"},{"key":"174_CR21","unstructured":"Dutch Anticoagulation Cinics, Nederlandse Trombosediensten. Trombosedienst locaties. 2015. http:\/\/www.fntnl\/trombosediensten\/trombosedienst-locatieshtml . Accessed on April 9th 2015."},{"issue":"10","key":"174_CR22","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2165\/00019053-200624100-00009","volume":"24","author":"P Sullivan","year":"2006","unstructured":"Sullivan P, Arant T, Ellis S, Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics. 2006;24(10):1021\u201333.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"174_CR23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11239-013-1048-z","volume":"38","author":"A Amin","year":"2014","unstructured":"Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, et al. Estimation of the impact of warfarin\u2019s time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. J Thromb Thrombolysis. 2014;38(2):150\u20139.","journal-title":"J Thromb Thrombolysis"},{"issue":"3015","key":"174_CR24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"1098","author":"J Cramer","year":"2008","unstructured":"Cramer J, Roy A, Burrell A, Fairchild C, Fuldeore M, Ollendorf A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;1098(3015):44\u20137.","journal-title":"Value Health"},{"key":"174_CR25","unstructured":"Dutch Foundation of Pharmaceutical Statistics S. Data en feiten. 2012. http:\/\/www.sfknl\/pdf-documenten\/data-en-feiten\/SFKDataenfeiten2013pdf . Accessed 12 Mar 2014."},{"key":"174_CR26","unstructured":"World Health Organization Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. Oslo: WHO. 2004. http:\/\/www.whocc.no\/filearchive\/publications\/1_2013guidelines.pdf . Accessed July 2015."},{"issue":"7","key":"174_CR27","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.amjmed.2009.11.025","volume":"123","author":"I Ogilvie","year":"2010","unstructured":"Ogilvie I, Newton N, Welner S, Cowell W, Lip G. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638\u201345.","journal-title":"Am J Med"},{"key":"174_CR28","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s11239-011-0561-1","volume":"31","author":"E Nutescu","year":"2011","unstructured":"Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Throm Thrombolysis. 2011;31:326\u201343.","journal-title":"J Throm Thrombolysis"},{"key":"174_CR29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev-pharmtox-011711-113247","volume":"52","author":"T Blaschke","year":"2012","unstructured":"Blaschke T, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2012;52:275\u2013301.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"174_CR30","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/europace\/euu319","volume":"17","author":"J Beyer-Westendorf","year":"2015","unstructured":"Beyer-Westendorf J, F\u00f6rster K, Ebertz F, Gelbricht V, Schreier T, G\u00f6belt M, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients results from the Dresden non-interventional oral anticoagulation registry. Europace. 2015;17(4):530\u20138.","journal-title":"Europace"},{"issue":"6","key":"174_CR31","first-page":"1807","volume":"25","author":"A Stuurman-Bieze","year":"2014","unstructured":"Stuurman-Bieze A, Hiddink E, van Boven J, Vegter S. Proactive pharmaceutical care interventions decrease patients\u2019 nonadherence to osteoporosis medication. Osteoporos Int. 2014;25(6):1807\u201312.","journal-title":"Osteoporos Int"},{"issue":"8","key":"174_CR32","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1055\/s-0034-1395156","volume":"40","author":"D Suryanarayan","year":"2014","unstructured":"Suryanarayan D, Schulman S. When the rubber meets the road: adherence and persistence with non-vitamin K antagonist oral anticoagulants and old oral anticoagulants in the real world\u2014a problem or a myth ? Semin Thromb Hemost. 2014;40(8):852\u20139.","journal-title":"Semin Thromb Hemost"},{"issue":"10","key":"174_CR33","first-page":"392","volume":"2013","author":"S Ewen","year":"1007","unstructured":"Ewen S, Retting-Ewen V, Mahfoud F, Bohm M, Laufs U. Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol. 1007;2013(10):392.","journal-title":"Clin Res Cardiol"},{"issue":"7","key":"174_CR34","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1185\/03007995.2014.907140","volume":"30","author":"F Lalibert\u00e9","year":"2014","unstructured":"Lalibert\u00e9 F, Cloutier M, Nelson W, Coleman C, Pilon D, Olson W, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2014;30(7):1317\u201325.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"174_CR35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00228-007-0268-6","volume":"63","author":"T Schalekamp","year":"2007","unstructured":"Schalekamp T, van Geest-Daalderop J, Kramer M, van Holten-Verzantvoort A, de Boer A. Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction. Eur J Clin Pharmacol. 2007;63(4):335\u201343.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"174_CR36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ahj.2014.04.007","volume":"168","author":"P Hess","year":"2014","unstructured":"Hess P, Mirro M, Diener H, Eikelboom J, Al-Khatib S, Hylek E, et al. Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: proceedings, Washington, DC, December 3\u20134, 2012. Am Heart J. 2014;168(3):239\u201347.","journal-title":"Am Heart J"},{"issue":"5","key":"174_CR37","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.thromres.2014.01.016","volume":"133","author":"A Minno Di","year":"2014","unstructured":"Di Minno A, Spadarella G, Tufano A, Prisco D, Di Minno G. Ensuring medication adherence with direct oral anticoagulant drugs: lessons from adherence with vitamin K antagonists (VKAs). Thromb Res. 2014;133(5):699\u2013704.","journal-title":"Thromb Res"},{"issue":"1","key":"174_CR38","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/europace\/eut243","volume":"16","author":"B Vrijens","year":"2013","unstructured":"Vrijens B, Urquhart J. From monitoring to vigilance about patient adherence to new oral anticoagulants. Europace. 2013;16(1):149.","journal-title":"Europace."},{"issue":"1","key":"174_CR39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2710.2008.00878.x","volume":"33","author":"H Buurma","year":"2008","unstructured":"Buurma H, Bouvy ML, De Smet PAGM, Floor-Schreudering A, Leufkens HGM, Egberts ACG. Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther. 2008;33(1):17\u201323.","journal-title":"J Clin Pharm Ther"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-015-0174-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-015-0174-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-015-0174-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T23:11:06Z","timestamp":1653001866000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-015-0174-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,5]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["174"],"URL":"https:\/\/doi.org\/10.1007\/s11096-015-0174-4","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,5]]}}}